spacer
home > > autumn 2008 > lifecycle conundrum
PUBLICATIONS


Lifecycle Conundrum

The pharmaceutical industry has entered a period of evolution and the next five to 10 years are certainly set to be interesting. Undoubtedly these are challenging times for the traditional model of large pharmaceutical companies, where each have a handful of major blockbuster products which, in turn, help to propagate the next round of R&D, whilst also returning a healthy profit on investment. With the recent decline in pipeline products passing through Phase III trials, it is an ageing product portfolio which is sustaining R&D.

These older products are soon to be open to legitimate generic competition and concurrently there has been a large increase in the number of specialised and generic companies bringing products rapidly to market, increasing the level of competition in the sector. Counterbalanced against both branded and generic medicines has been the explosion in counterfeits flooding the market, aided by the global expansion of the internet and direct consumer marketing.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Claire Madden-Smith is the Commercial Director at Molecular Profiles, a CRO providing advanced analysis, consultancy and formulation support to the pharmaceutical and biopharmaceutical industry. Claire completed her PhD in Physical Chemistry in 1998 and joined Molecular Profiles in 2001, providing advanced analysis and testing for development, manufacturing and intellectual property issues. Claire has presented extensively around the globe on analysis and understanding of drug delivery systems and is currently the Chair of the Marketing Committee of the Controlled Release Society and a committee member of the Material Science Focus Group of the British Academy of Pharmaceutical Sciences.
spacer
Dr Claire Madden-Smith
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals initiates partnership with American Biotech Zhittya for Parkinsonís disease treatment

3P and Zhittya began their relationship at the beginning of 2019 with 3P being selected as the CDMO to transfer the process for scaling up and performing cGMP manufacturing for clinical studies. After successfully achieving transfer of the process, 3P anticipates manufacturing of the first cGMP batch by the second quarter of 2020.
More info >>

White Papers

Crunch Time: The Impact of Serialisation Requirements on Packaging Operations

PCI Pharma Services

The deadlines for including unique product identifiers on prescription drugs is putting a strain on multiple parts of the industry, much of which is ill-prepared to meet the target. Here, we look to the experience of a company that is ahead of the curve for lessons on how to manage and ease the transition to serialisation.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement